- About
- Advertise / Support
- Contact
- CancerNetwork.com
- TargetedOnc.com
- OncLive.com
- OncNursingNews.com
- Terms & Conditions
- Privacy
- Do Not Sell My Information
© 2024 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
FDA Expands Mylotarg Approval to Include Children With Newly-Diagnosed CD33-Positive AML
Ryan McDonald, Associate Editorial Director for CURE®, has been with the team since February 2020 and has previously covered medical news across several specialties prior to joining MJH Life Sciences. He is a graduate of Temple University, where he studied journalism and minored in political science and history. He considers himself a craft beer snob and would like to open a brewery in the future. During his spare time, he can be found rooting for all major Philadelphia sports teams. Follow Ryan on Twitter @RMcDonald11 or email him at rmcdonald@curetoday.com.
The Food and Drug Administration (FDA) extended the indication of Mylotarg (gemtuzumab ozogamicin) to include the treatment of children aged one month or older with newly diagnosed CD33-positive acute myeloid leukemia (AML).
The Food and Drug Administration (FDA) extended the indication of Mylotarg (gemtuzumab ozogamicin) to include the treatment of children aged one month or older with newly diagnosed CD33-positive acute myeloid leukemia (AML).
The FDA, previously in 2017, approved the drug for the treatment of adults with newly diagnosed CD33-positive AML, as well as children aged two years and older with CD33-positive relapsed/refractory AML.
The agency based its latest decision on data from the multicenter, randomized AAML0531 trial which comprised 1,063 patients with newly diagnosed AML aged 0 to 29 years. During the trial, patients either received a five-cycle chemotherapy alone or with Mylotarg.
Approximately 48% of patients who received Mylotarg and chemotherapy did not experience induction failure, relapse, or death at five years, compared to 40% who received chemotherapy alone. However, there was no difference between the two arms regarding overall survival.
Common severe side effects that occurred in more than 5% of patients who received Mylotarg included — but were not limited to — decreased appetite, diarrhea, nausea and hypotension.
Check back later for you what you need to know about this approval.
Related Content:
